George Chaconas, MD
Family Medicine · Wirtz, VANPI 1720069354
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,027 of the $20,222 with a category attached, or 84.2%. Amgen accounts for 78.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $14,785 and has fallen 99.3% since, to $100 in 2025. Among family medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $100.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$16K
- Esperion Therapeutics, Inc.$2K
- Lilly USA, LLC$555
- Novartis$308
- Novo Nordisk$298
- AstraZeneca$223
- plus $628 from 13 others
What the payments were for
- Speaking & faculty fees$17,02784%
- Travel & lodging$2101%
- Food & beverage$2,96015%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 49 | $15,905 |
| Esperion Therapeutics, Inc. | 9 | $2,306 |
| Lilly USA, LLC | 49 | $555 |
| Novartis | 21 | $308 |
| Novo Nordisk | 23 | $298 |
| AstraZeneca | 14 | $223 |
| Amarin Pharma, Inc. | 10 | $182 |
| Regeneron Healthcare Solutions, Inc. | 5 | $80 |
| GSK | 5 | $79 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| AbbVie | 3 | $52 |
| Medicure Pharma Inc. | 1 | $26 |
| Pfizer | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,222 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 102 | $120,754 |
| OzempicSemaglutide | 68 | $91,987 |
| EliquisApixaban | 64 | $79,881 |
| Praluent PenAlirocumab | 51 | $54,851 |
| MounjaroTirzepatide | 35 | $36,709 |
| RybelsusSemaglutide | 14 | $25,544 |
| JardianceEmpagliflozin | 13 | $21,069 |
| NexletolBempedoic Acid | 13 | $13,129 |
| LivaloPitavastatin Calcium | 13 | $12,780 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,739 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,789 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $8,333 |
| Ezetimibe | 212 | $6,704 |
| Icosapent Ethyl | 13 | $6,443 |
| Rosuvastatin Calcium | 485 | $4,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $298 | $117,53182 claims |
| PfizerEliquis, Paxlovid | $23 | $81,31086 claims |
| Lilly USA, LLCMounjaro | $555 | $36,70935 claims |
| Esperion Therapeutics, Inc.Nexletol | $2,306 | $13,12913 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $73 | $12,78013 claims |
| GSKBreo Ellipta | $79 | $8,33313 claims |
| AbbVieSynthroid | $52 | $3,41248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Wirtz
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.